Campbell & CO Investment Adviser LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 20.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,219 shares of the company’s stock after selling 1,363 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Novo Nordisk A/S were worth $475,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of NVO. Jennison Associates LLC raised its position in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after acquiring an additional 11,727,507 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Novo Nordisk A/S by 1,514.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,785,560 shares of the company’s stock valued at $602,435,000 after buying an additional 3,551,104 shares during the period. Everett Harris & Co. CA grew its stake in shares of Novo Nordisk A/S by 98.6% in the 3rd quarter. Everett Harris & Co. CA now owns 6,539,202 shares of the company’s stock valued at $594,675,000 after buying an additional 3,246,806 shares during the period. WCM Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 88.3% in the 3rd quarter. WCM Investment Management LLC now owns 6,528,911 shares of the company’s stock valued at $594,000,000 after buying an additional 3,061,251 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Novo Nordisk A/S by 45.4% in the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after buying an additional 1,571,747 shares during the period. 6.41% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 16th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Cantor Fitzgerald lifted their price target on Novo Nordisk A/S from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. TD Cowen lifted their price target on Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, December 4th. Finally, UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $121.25.
Novo Nordisk A/S Price Performance
NVO stock opened at $120.54 on Tuesday. The company has a market capitalization of $540.93 billion, a P/E ratio of 44.56, a price-to-earnings-growth ratio of 2.01 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a 52-week low of $67.66 and a 52-week high of $121.65. The business has a 50-day simple moving average of $106.00 and a two-hundred day simple moving average of $86.35.
Novo Nordisk A/S Increases Dividend
The firm also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th will be paid a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date is Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is presently 22.92%.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
- Five stocks we like better than Novo Nordisk A/S
- Learn Technical Analysis Skills to Master the Stock Market
- Salesforce and MongoDB: 2 must-own tech stocks
- How to Invest in Solar Energy
- Udemy stock got boosted by analysts, massive growth at discounts
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 attractive stocks that insiders are buying
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.